



Clinical Proteomics in Proliferative Disorders

Guest Editors:

Dr. Attila Marcell Szász

Division of Oncology,
Department of Internal Medicine
and Oncology, Semmelweis
University, 1083 Budapest,
Hungary

Dr. György Marko-Varga

Department of Biomedical,
Engineering, Lund University,
22100 Lund, Sweden

Deadline for manuscript
submissions:

closed (30 March 2022)

Message from the Guest Editors

Dear Colleagues,

Neoplastic and non-neoplastic disorders of human pathology encompass a wide spectrum of disease states with various prognostics. Our ultimate goal is to discover and implement diagnostic and therapeutic tools to improve outcomes and the life quality of patients. In recent decades, we have witnessed the advent of transcriptomics and genomics which today are the cornerstones of clinical decision making in modern molecularly driven therapeutics. Proteomics will bridge the gap between genetics and the resulting phenotypes, which will also improve our understanding of human diseases like never before.

In this Special Issue, we seek contributions which improve our understanding of tumor biology or non-neoplastic proliferative disorders with a direct implication for patient care. Results of measurements performed on human tissue or clinical data are encouraged. Original reports, review articles, meta-analyses, and clinical trial reports which contain protein-level investigation with direct implication in patient care are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)